Having completed its transformation into a pure-play innovative medicines business in 2023 following the spin-off of the Sandoz business, Novartis AG is on the look-out for more bolt-on deals in its four core therapeutic areas – cardiovascular/renal/metabolic, immunology, neuroscience and oncology – but the likelihood of the Swiss giant jumping into the obesity space is looking faint.
That was the view of chief financial officer Harry Kirsch as he presented Novartis's financials for the fourth quarter to journalists this morning (31 January). The year began with rumors that the company had pursued and then pulled out of talks with Cytokinetics, Inc., which moved towards the top of the takeover target list just before Christmas on strong Phase III data in hypertrophic cardiomyopathy for aficamten
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
